1% org. sales (ABGSCe 19%), 4.1% margin (ABGSCe 3.8%) Q3 in isolation would yield limited estimate r...
Redeye updates on G5 following the company’s Q3-results which came in lower than expected.
Redeye states that the Smart Eye investment case is now playing out exactly according to plan.
Redeye comments on Lytix’ third results in 2023. In October, the first readout from the phase II tri...
4.3% organic sales growth Improved cash flow generation Near-term uncertainty, but long-term potenti...
Sales of SEK 33.4m, up 50.3% y-o-y, adj. EBIT SEK -2.
Improved org. growth on price increases '23e EBITA +3%, '24e-'25e largely unchanged 11x-9x '23e-'24e...
Q3 income 6% below our ABGSCe due to lower NCI... .
Redeye notes that the Neonode Q3'23 report was weaker than expected.
Redeye was hoping for a bit more, particularly in terms of top-line.
We expect a solid Q3 with 12% organic sales growth 15% EBIT growth y-o-y in Q3e Inera framework agre...
Redeye is encouraged by the news that Kontigo Care has partnered strategically with its first corpor...
Redeye provides its comment on Mendus’ Q3 2023 report.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Xspray Pharma.
Emission avklarad Diamyd meddelade nyligen det slutgiltiga utfallet i sin företrädesemission.
Realistiskt att nå SPARKLE-resultat med nuvarande kassa Ascelia levererade en Q3-rapport som var enl...
Redeye is positively surprised by Bredband2’s Q3 performance, where its efforts to increase margins ...
Marimekko reported Q3 figures that were largely in line with our estimates.
Sales +1% and company adj. EBITDA SEK +4m vs. ABGSCe Circular Energy drives growth and improved prof...
Redeye sees a rather soft Q3 report from Xavi, with sales and adjusted EBIT coming below our expecta...
